Epitalon
Epithalon, Epithalone, AEDG peptide, Ala-Glu-Asp-Gly, AE-0 peptide
Epitalon is a synthetic four-amino-acid peptide designed in Russia in the 1990s as a defined chemical stand-in for Epithalamin, a crude bovine pineal gland extract. It is promoted as a telomerase activator and anti-ageing agent. Essentially all of the supporting data are cell-culture and rodent experiments from a single research group, and the widely cited human longevity results were obtained with the pineal extract, not with this peptide.
Mechanism
Epitalon is a tetrapeptide with no known cell-surface receptor. The mechanism proposed by the Khavinson group at the St Petersburg Institute of Bioregulation and Gerontology is that very short peptides pass through the cell and nuclear membranes without a transporter and bind directly to DNA in the minor groove of promoter regions, or to histone proteins, altering chromatin accessibility and thereby switching specific genes on or off. Fluorescence-labelling work has shown AEDG entering HeLa cell cytoplasm, nucleus and nucleolus and binding labelled deoxyribo-oligonucleotides in vitro with some discrimination between sequences and cytosine methylation states, which establishes that nuclear entry and DNA contact are physically possible; it does not establish that this is how any biological effect is produced. The 'no transporter needed' premise should also be held loosely: a 2023 modelling study from the same group proposed instead that AEDG and related ultrashort peptides are substrates of the LAT1, LAT2 and PEPT1 membrane transporters, which is a different account of how they get into cells.
The headline claim is telomerase induction. In telomerase-negative human fetal fibroblasts, Epitalon was reported to induce expression of hTERT, the catalytic subunit of telomerase, restore enzymatic telomerase activity and lengthen telomeres, extending the culture's replicative lifespan past the Hayflick limit. Secondary mechanisms proposed include stimulation of pineal melatonin synthesis and restoration of circadian melatonin rhythm in aged animals, modulation of interleukin-2 transcription, and reduction of lipid peroxidation markers. It is worth being precise about what would follow even if the telomerase finding were solid: reactivating telomerase in somatic cells is a double-edged intervention, since telomerase reactivation is also one of the defining acquired capabilities of cancer cells.
What the research shows
The primary telomerase result is a single 2003 report of three pages in Bulletin of Experimental Biology and Medicine describing hTERT induction and telomere elongation in human fetal fibroblast culture. It has not been independently replicated in a Western laboratory in the two decades since, which for a claim of this magnitude is the single most important fact about the compound.
The rodent work is more substantial in volume, and it needs reporting accurately, because it is routinely misdescribed in both directions. In the 2003 female outbred SHR mouse lifespan study, 54 mice per group received 1.0 microgram per mouse (roughly 30-40 micrograms per kilogram) subcutaneously on five consecutive days each month from three months of age until natural death. Epitalon did not change mean lifespan and did not change total spontaneous tumour incidence. It did increase maximum lifespan by 12.3 per cent and the lifespan of the last 10 per cent of survivors by 13.3 per cent, slowed the age-related loss of oestrous function, reduced chromosome aberrations in bone marrow cells by 17.1 per cent, and inhibited leukaemia development sixfold. In HER-2/neu transgenic mice, Epitalon reduced the cumulative number and maximum size of mammary tumours and produced a 3.7-fold reduction in HER-2/neu mRNA in tumour tissue, though overall tumour incidence was not reduced. In rats exposed to constant light or constant darkness, it partially offset the accelerated ageing and tumour burden those regimens produce. These are consistent findings, but they come overwhelmingly from one group and one collaborative network.
The human evidence is where the marketing and the literature diverge sharply. The frequently cited claim that pineal peptides reduced mortality several-fold in elderly people comes from a 2003 Neuroendocrinology Letters paper covering 266 subjects followed for six to eight years, and that study administered Epithalamin, the bovine pineal extract, and Thymalin, a thymus extract, not synthetic Epitalon. The Epithalamin-alone mortality reduction was 1.6- to 1.8-fold; the headline 4.1-fold figure applies only to a subgroup given both extracts annually for six years. The study was not randomised or blinded to modern standards, was not pre-registered, reported no protocol, and has never been replicated. There is no registered interventional clinical trial of Epitalon on ClinicalTrials.gov. A 2025 review in International Journal of Molecular Sciences summarising 25 years of work concluded that the mechanisms remain incompletely understood and that physicochemical and structural characterisation lags far behind the biological claims.
Evidence assessment
Preclinical only
All Epitalon-specific data are cell-culture and rodent experiments from essentially one research network; the human longevity results routinely attributed to it were generated with a bovine pineal extract, not this peptide, and no registered clinical trial of Epitalon exists.
Tiers are applied consistently across the library and re-checked when new trials read out. Read the grading method.
Key studies
Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells Preclinical only
Addition of Epitalon induced expression of the telomerase catalytic subunit, enzymatic telomerase activity and telomere elongation in culture.
Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice Preclinical only
No effect on mean lifespan and no effect on total spontaneous tumour incidence; maximum lifespan increased 12.3 per cent, lifespan of the last 10 per cent of survivors increased 13.3 per cent, bone marrow chromosome aberrations reduced 17.1 per cent, leukaemia development inhibited sixfold.
Inhibitory effect of the peptide epitalon on the development of spontaneous mammary tumors in HER-2/neu transgenic mice Preclinical only
Reduced the cumulative number and maximum size of mammary tumours and reduced HER-2/neu mRNA expression in tumours 3.7-fold; the size but not the number of lung metastases was reduced.
Peptides of pineal gland and thymus prolong human life Limited evidence
Reported mortality reductions of 1.6- to 1.8-fold with the pineal extract alone, 2.0- to 2.1-fold with the thymic extract alone, 2.5-fold with both, and 4.1-fold in a subgroup given both annually for six years.
AEDG Peptide (Epitalon) Stimulates Gene Expression and Protein Synthesis during Neurogenesis: Possible Epigenetic Mechanism Preclinical only
AEDG raised protein levels and mRNA expression (1.6- to 1.8-fold) of the neurogenic differentiation markers Nestin, GAP43, beta-Tubulin III and Doublecortin; modelling suggested preferential binding to histones H1/3 and H1/6.
Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA Preclinical only
Labelled epithalon (AEDG), pinealon (EDR) and testagen (KEDG) were detected in HeLa cytoplasm, nucleus and nucleolus, and quenching constants indicated sequence-dependent and methylation-status-dependent binding to oligonucleotides.
Overview of Epitalon - Highly Bioactive Pineal Tetrapeptide with Promising Properties Preclinical only
Concluded that proposed mechanisms remain incompletely understood and that structural and physicochemical characterisation lags well behind the volume of biological claims.
Safety
No formal human safety database exists. Rodent toxicology from the originating group reported no overt toxicity, and the 2003 SHR lifespan study explicitly concluded that long-term administration was safe in mice, but those studies were not conducted to modern regulatory standards and were not designed primarily as toxicology. Because there is no controlled human exposure data, the honest statement is that the adverse-effect profile is unknown rather than benign. Two specific concerns deserve naming: any agent that genuinely reactivated telomerase in somatic tissue would carry a theoretical oncogenic risk that has never been formally assessed in humans, and material sold online is unregulated, so purity, identity, endotoxin content and sterility are unverified.
Regulatory status
| Jurisdiction | Status |
|---|---|
| United Kingdom | No marketing authorisation from the MHRA. Under the Human Medicines Regulations 2012, a product presented or supplied for a physiological effect in humans is a medicinal product regardless of any 'not for human consumption' label, so consumer-facing supply sits outside the law rather than in a grey area. |
| United States | Not approved by the FDA for any indication and not the subject of any registered interventional trial. Sold as a 'research chemical'. That phrase is a commercial disclaimer, not a regulatory category: it allows an unapproved compound to be shipped to consumers while the seller disclaims the human use everyone involved anticipates. |
| WADA (sport) | Not individually named on the WADA Prohibited List, but captured by section S0 (non-approved substances), which prohibits at all times any pharmacological substance with no current approval by any government health authority for human therapeutic use. |
Questions
There is no human study showing that it does. The telomere-lengthening result comes from a single 2003 experiment in cultured human fetal fibroblasts from one Russian laboratory, and it has never been independently replicated. No trial has measured telomere length in people given Epitalon.
Partly, and the detail matters. In the 2003 SHR mouse study it did not change mean lifespan, but it did increase maximum lifespan by 12.3 per cent and the lifespan of the longest-lived 10 per cent by 13.3 per cent. It also did not reduce overall spontaneous tumour incidence, though it did reduce leukaemia specifically. Promotional summaries and sceptical summaries both tend to quote only the half that suits them.
No, and the distinction matters. Epithalamin is a crude peptide extract of bovine pineal gland. Epitalon is a defined synthetic tetrapeptide (Ala-Glu-Asp-Gly) modelled on it. The much-quoted human study reporting reduced mortality in elderly subjects used the extract, not the synthetic peptide.
No registered interventional trial of Epitalon appears on ClinicalTrials.gov. Every efficacy claim in circulation traces back to cell-culture work, rodent studies, or the pineal-extract literature.
It has no medicines authorisation in the US or UK. Sellers use the phrase 'for research use only', which is a legal shield rather than a regulatory status: it lets an unapproved compound be sold to consumers while the seller disclaims the human use that is obviously intended.